Liraglutide Research Reference

Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.

Researched for: Liraglutide evidence and protocol review

Metabolic Research peptide Injection solution needs_revision Best effort · source review pending

Also known as: Victoza, Saxenda

Open in Calculator ← Compound Index All Tools

Best-effort research profile: this record has not passed full two-source scientific verification. Descriptive fields, research protocols, storage/handling notes, and interaction guidance below are shown with their evidence labels, but calculator presets and exact dosing math remain hidden until the record is verified or reaches Community-Supported status.

Quick Facts

Reference Sizes

18 mg/3 mL multidose pen

Storage

No approved consumer storage standard exists for this presentation; follow the lot-specific COA and validated stability data

Solubility

Form, salt, and formulation dependent; verify the lot-specific COA

Best-Effort Research Profile

Liraglutide is a first-generation GLP-1 receptor agonist (97% sequence homology to endogenous human GLP-1) with a half-life of ~13 hours requiring once-daily dosing. FDA approval for chronic weight management (Saxenda, 3.0 mg) was based on the Phase 3 SCALE trial program; at 56 weeks, liraglutide 3.0 mg produced a mean 8.0% weight reduction versus 2.6% with placebo (ClinicalTrials.gov NCT01272232). Also approved as Victoza (1.8 mg) for type 2 diabetes.

Source review pending. This descriptive profile is shown from the available source material as a best-effort educational reference. It has not passed the full verification bar and is not a dosing instruction, medical claim, or treatment recommendation.

Research Profile

Half-Life

~13 hours (requires once-daily dosing)

Onset

Weight/glycemic effects develop over the 56-week SCALE trial timeline as dose is titrated

Administration Routes (Research)

Reported Research Effects

Glycemic control via GLP-1 receptor agonism
Weight reduction (SCALE trial program)

Reported Research Side Effects

Human safety, pharmacokinetics, and interaction data are incomplete

Data source: Primary literature, regulator records, trial registries, and identity-specific evidence search

Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.

Research Protocols Reported in the Literature

Week 1: 0.6 mg daily; week 2: 1.2 mg daily; week 3: 1.8 mg daily; week 4: 2.4 mg daily; week 5 onward: 3 mg daily for adult chronic weight management [SC; 4-week escalation then maintenance; Daily]Source: current SAXENDA prescribing information

Research Notes

The former record incorrectly treated 1.8 mg as a weight-management maintenance dose. Victoza and Saxenda have different indications and target doses.

Supplementary research context only. Not medical advice or a treatment recommendation.

Sources Under Review

SAXENDA liraglutide prescribing information — DailyMed (NIH)
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143

Suggest a community source

Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.

Related Research Tools

Reconstitution CalculatorConcentration, draw volume, per-unit amounts Unit Convertermg, mcg, mL, units conversion Compound CompareSide-by-side comparison tool Cost CalculatorCost per mg, mcg, per-draw

Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.